PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31810748-0	2020	The antidepressant-like effects of fluvoxamine in mice involve the mTOR signaling in the hippocampus and prefrontal cortex.	Fluvoxamine	35-46	mechanistic target of rapamycin kinase	Mus musculus	67-71	
31810748-3	2020	Therefore, this study aims to evaluate whether mTOR underlies the antidepressant-like effects of fluvoxamine.	Fluvoxamine	97-108	mechanistic target of rapamycin kinase	Mus musculus	47-51	
31810748-7	2020	It was found that fluvoxamine treatment fully reversed the effects of CUMS on the mTOR signaling in the hippocampus and PFC, and the usage of rapamycin significantly prevented the antidepressant-like effects of fluvoxamine in the CUMS model of depression.	Fluvoxamine	18-29	mechanistic target of rapamycin kinase	Mus musculus	82-86	
31810748-8	2020	Taken together, the mTOR system is involved in the antidepressant mechanisms of fluvoxamine.	Fluvoxamine	80-91	mechanistic target of rapamycin kinase	Mus musculus	20-24	
24396420-8	2014	These results suggest that sigma1 receptors mediate fluvoxamine-elicited changes in the expression levels of mTOR, Camk2gamma and GSK-3beta in N2a cells, which indicates that sigma1 receptors are likely to be involved in the pharmacological effects of fluvoxamine.	Fluvoxamine	52-63	mechanistic target of rapamycin kinase	Mus musculus	109-113	
24396420-0	2014	Effects of BD1047, a sigma1 receptor antagonist, on the expression of mTOR, Camk2gamma and GSK-3beta in fluvoxamine-treated N2a cells.	Fluvoxamine	104-115	mechanistic target of rapamycin kinase	Mus musculus	70-74	
24396420-8	2014	These results suggest that sigma1 receptors mediate fluvoxamine-elicited changes in the expression levels of mTOR, Camk2gamma and GSK-3beta in N2a cells, which indicates that sigma1 receptors are likely to be involved in the pharmacological effects of fluvoxamine.	Fluvoxamine	252-263	mechanistic target of rapamycin kinase	Mus musculus	109-113